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Objective 
RAPID3 is a patient reported, composite index, designed for feasibility in clinical care. RAPID3 
was developed in rheumatoid arthritis, but has been found useful in many rheumatic 
diseases. We analysed RAPID3 in patients with psoriatic arthritis (PsA).  
Methods 
Post-hoc analyses were performed on two independent datasets, the tight control of PsA 
(TICOPA) trial, and the long-term outcome in PsA study (LOPAS II), an observational cohort. 
RAPID3 (0-30) is calculated as the total of three 0-10 scores for HAQ-DI (recalculated from 0-
3), pain visual analog scale (VAS), and global VAS. Data were compared to the PsA disease 
activity score (PASDAS) and disease activity in psoriatic arthritis (DAPSA) and other available 
clinical measures, according to Spearman correlation coefficients, standardised response 
mean (SRM), standard error of the mean (SEM), smallest detectible difference (SDD), 
minimally important difference (MID in patients who improved) and receiver-operating 
characteristic (ROC) curves. RAPID3 remission was compared to criteria for both standard 
minimal disease activity (MDA) and very low disease activity (VLDA).  
Results 
RAPID3 was correlated significantly with PASDAS in TICOPA (r=0.79, p<0.01) and with DAPSA 
in LOPAS (rho=0.59, p<0.01) and with most other measures in both datasets. RAPID3 
discriminated between tight control and standard care in TICOPA at 48 weeks at levels 
comparable to DAPSA and the PASDAS (p<0.01). RAPID3 remission discriminated treatment 
groups in TICOPA intermediate between MDA and VLDA criteria.  
Conclusion 
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RAPID3 appears comparably informative to PASDAS and DAPSA in PsA, with greater 
feasibility for routine clinical care. 
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Significance and Innovation 
 RAPID3 correlates well with more comprehensive PsA-specific outcome measures, both 
those assessing arthritis (DAPSA) and global disease activity (PASDAS) 
 RAPID3 can differentiate treatment groups in the TICOPA clinical trial. 
 A modified RAPID3 including a skin VAS was not clearly superior in performance but 
levels of skin disease were low in the datasets used. 
 RAPID3 remission correlates well at the individual patient level with other remission 
measures but physical examination is still required for optimal clinical decision making.  
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Psoriatic arthritis (PsA) is a complex disease involving both the musculoskeletal and 
cutaneous systems.  Many outcome measures have been developed specifically for PsA to 
reflect both systems, with composite indices, which may include assessment of arthritis 
(both peripheral and axial), enthesitis, dactylitis, skin and nail psoriasis, and patient-
reported outcomes (1).  Such composite indices are used widely in clinical trials, but 
generally not incorporated into routine practice due to their complexity(1).  The only 
quantitative data available in routine care of many PsA (and other rheumatology) patients 
are laboratory tests, with significant limitations.  
 
Routine assessment of patient index data 3 (RAPID3) is an index composed of only the 3 
patient self-reported measures from the rheumatoid arthritis (RA) Core Data Set(2): physical 
function on a health assessment questionnaire (HAQ) or its multidimensional version 
(MDHAQ), and pain and patient global estimate on two 0-10 visual analogue scales (VAS) (3). 
RAPID3 was developed initially in RA, but subsequently has been found informative in axial 
spondyloarthritis(4-7), osteoarthritis(8), gout(9) systemic lupus erythematosus(10) and other 
arthritides(9, 11-13).  Whilst the primary goal for RAPID3 was feasibility in routine care to 
provide quantitative data for prognosis, management and outcomes, scores generally have 
been found quite comparable to more elaborate disease-specific indices (14).  
 
This study assessed the potential value of RAPID3 to depict clinical status compared to 
PASDAS, DAPSA, and other measures in two datasets, the tight control of PsA (TICOPA) study, 
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a clinical trial, and the long term outcome of PsA study (LOPAS II), an observational cohort. 
An important consideration that RAPID3 may not address the dermatological aspects of PsA 
effectively was analysed using a modified RAPID3Ps, which included a fourth item, a VAS scale 
for skin disease activity that could be added to the original RAPID3. 
Materials and Methods 
Data.  Post-hoc analyses were performed on two independent datasets to study the value of 
RAPID3 in PsA.  First, we analysed data from the tight control of PsA (TICOPA) clinical trial 
(ClinicalTrials.gov NCT01106079, ISCRCTN30147736), to assess its performance in a 
controlled trial setting.  Second, we used data from the long-term outcomes in PsA study 
(LOPAS II) to assess its performance in an observational cohort setting (15).  
TICOPA trial. The TICOPA trial is a UK multicentre randomised controlled trial, in which 206 
adults with early psoriatic arthritis were randomly assigned on a 1:1 ratio  either to tight 
control with a step-up regimen aiming for minimal disease activity using methotrexate, 
combination disease-modifying anti-rheumatic drugs (DMARDs) and anti-tumour necrosis 
factor drugs as required or to standard care(16).  In the TICOPA dataset, the PsA disease 
activity score (PASDAS) was used as the gold standard comparator, as this composite measure 
addresses all aspects of psoriatic disease(17).  Differences between treatment groups 
according to RAPID3, PASDAS and other PsA measures were compared.   
LOPAS II observational cohort.  LOPAS II is a prospective, multicentre observational cohort 
study to investigate the effect of conventional synthetic disease modifying anti rheumatic 
drugs (csDMARD) and anti-Tumour Necrosis Factor inhibitors (anti-TNF) on clinical and 
patient reported outcomes among PsA patients of any age and disease duration who fulfilled 
the classification for psoriatic arthritis (CASPAR) criteria(18) and were being commenced on 
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csDMARD or anti-TNF as part of routine clinical care. In the LOPAS study, analyses were 
undertaken on participants with complete data at baseline and three months follow up. The 
Disease Activity in Psoriatic Arthritis (DAPSA) was used as a composite measure of articular 
disease (calculated from the 66/ 68 tender and swollen joints count, c reactive protein, 
patient global assessment and pain visual analogue scales)(19). The required items for MDA 
and PASDAS were not all available in this dataset. 
RAPID3 index. RAPID3 scores are calculated as the 0-30 sum of the three 0-10 RA core data 
set measures of physical function, pain, and a patient global estimate (3). Physical function 
is assessed on a Health Assessment Questionnaire (HAQ) (20) or multidimensional version  
(MDHAQ); activities are scored 0-3 and the total of 0-30 or mean 0-3, are converted to a 0-
10 score.  Pain and a patient global estimate were scored in these studies on a (0 -10) visual 
analog scale (VAS) using the GRAPPA PsA global wording “In all the ways in which your 
psoriasis and arthritis, as a whole, affects you…”. In addition, a modified RAPID3 which 
included a VAS scale for skin disease activity as a fourth item was studied, because of 
consideration that the 3-item RAPID3 would not be informative concerning the 
dermatological aspects of PsA.  
 
The range for RAPID3 is 0-30 and severity categories have been defined for RA: ≤3 for 
remission, 3.1-6.0 for low, 6.1-12.0 for moderate, and >12 for high severity (21). These 
potential categories were studied in comparison with other remission and low disease 
categories from PsA specific measures, at both group and individual levels.  RAPID3 
remission was compared to both the standard Minimal Disease Activity (MDA) criteria(22) 
and the very low disease activity (VLDA) criteria(23), which  were developed specifically for 
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PsA and have been shown to correlate well with other disease activity measures(24, 25) in 
PsA.  MDA also is associated with physician and patient opinion of low disease activity using 
anchor questions(23), and has prognostic value for better functional outcome and lower 
rates of radiographic damage(26). The MDA criteria for PsA require meeting 5 of 7 cutpoints 
in 7 measures: HAQ≤0.5, patient global VAS≤20mm, patient pain VAS≤15mm (the three 
RAPID measures, though at different cut-points); tender joint count (TJC)≤1; swollen joint 
count (SJC) ≤1; enthesitis count≤1 and psoriasis area and severity index (PASI) ≤1 or body 
surface area (BSA) ≤3(22).  To meet VLDA criteria, all seven cut points must be met(23).  This 
endpoint has been investigated in view of the emphasis on remission as the ideal target for 
treatment(27); preliminary validation has indicated that it is a very stringent measure(23).  A 
more stringent method to assess remission based on RAPID3, with addition of whether a 
patient has 0 or1 vs >1 swollen joint (RAPID3SJC1)(28, 29) also was  analysed 
 
In studies of LOPAS II data, construct validity was assessed using Spearman correlation 
coefficients with other disease outcome measures. Agreement between the DAPSA and 
RAPID3 was determined on the Bland Altman plot(30) (after rescaling both measures to 
allow comparison on the same plot). Responsiveness was assessed using Standard Error of 
the Mean (SEM), Standardised Response Mean (SRM) and Smallest Detectible Difference 
(SDD). The Minimally Important Difference (MID) was determined using the health based 
anchor method (mean change in score amongst patients who improved) and Receiver 
Operator Characteristic Curve (ROC) methods (the change in score at the top left corner of 
the curve representing the smallest amount of misclassification).  Responsiveness of the 
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measures as continuous variables and their correlations with other disease activity 
measures were assessed in both cohorts 
 
Results 
TICOPA clinical trial.  In the TICOPA study, the disease duration of patients was less than 24 
months and their mean age was 44 years.  RAPID3 scores were correlated significantly with 
PASDAS (Spearman’s correlation 0.80, p<0.01) at all baseline and follow up visits (figure 1), 
indicating construct validity.  RAPID3Ps (which includes a skin VAS) was also correlated highly 
with PASDAS at similar levels.  The change in score at follow up was also correlated 
significantly with the change in PASDAS (0.64, p<0.01).   
RAPID3 was highly discriminant of change in the tight control vs standard treatment groups 
(Table 1).  (t value -3.43, p<0.01) and superior to each individual measure.  Patient-reported 
measures were more discriminant than joint counts (Table 1).  RAPID3 also was similar in 
discrimination to the disease activity in PsA (DAPSA) score, but slightly less than PASDAS (table 
2).  When plotting mean scores for both PASDAS and RAPID3 in the TICOPA trial, similar 
responses are seen at each timepoint (figure S1).  
The proportions of patients who were classified as in remission according to RAPID3 and 
RAPID3SJC1 lies between MDA and VLDA (table 2), as might be expected.  RAPID3 NR and 
RAPID3SJC1 in TICOPA also were highly discriminant between treatment groups (table 2), 
although slightly lower than MDA and DAPSA remission.  At an individual (rather than group) 
level, exact agreement between MDA and RAPID3 remission was seen in 85.2% of patients at 
48 weeks.  Only five patients (of 67) in RAPID3 remission were not in MDA due to higher 
physician assessed disease activity.  By contrast, 22 patients were in MDA but did not meet 
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the RAPID3 remission levels due to high patient reported measures.  The majority of patients 
(58 of 67) in RAPID3 remission also met the more stringent RAPID3SJC1 criteria (RAPID3 
remission + SJC≤1)(28, 29).  
Agreement between RAPID3 remission and VLDA was slightly lower than MDA (percentage 
exact agreement (PEA) of 73.6%).  Compared to this more stringent target, 44 of the 67 
patients in RAPID3 remission were not in VLDA whilst only four patients were in VLDA but did 
not meet RAPID3 NR due to high patient reported measures.  This finding suggests that the 
RAPID3 remission cut off lies between MDA and VLDA in terms of disease activity cut off.  For 
those in RAPID3 remission, the levels of residual disease activity is shown in table S1.  The 
majority of patients have low levels of ongoing active disease including CRP which is normal 
in around 75% of patients.   
 
LOPAS observational study.  In the LOPAS study, the mean disease duration 5.8 years (sd 
7.77) and the mean age was 51 years.  RAPID3 scores correlated significantly with the DAPSA 
composite measure (Spearman correlation coefficient 0.59, p<0.01) as confirmed in figure 2, 
and with other patient reported outcomes: Joint VAS (0.83), EQ5D (0.65), FACIT fatigue (0.63). 
Correlation with clinical joint count and CRP was lower: tender joint count (0.39), swollen joint 
count (0.21), CRP (0.17).   No significant difference was seen between the response to 
treatment (within each independent treatment group) according to RAPID3 or DAPSA for 
either the TNF (p= 0.76) or DMARD (p=0.09) groups (Figure S1).  
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RAPID3 was responsive according to the mean change, SEM, SRM and SDD during follow up 
(Table 3). The MID for improvement using the anchor method for the RAPID3 was -8.1 (sd 5.9) 
and DAPSA -27.9 (sd 23.7). The MID using the ROC method (figure 3) for the RAPID3 was -5.1 
(AUC 0.84) and DAPSA -16.7 (AUC 0.75).  Using initiation of treatment (baseline visit) as a gold 
standard for active disease, only a small number of patients were potentially misclassified as 
being in remission or low disease activity by either score: DAPSA (2.3%) and RAPID3 (5%).  
RAPID3 was correlated significantly with the EQ5D, Joint VAS and FACIT fatigue, but at lower 
levels with clinical joint counts and the CRP. This finding highlights some disconnect between 
physician and patient reported outcomes. 
 
Discussion 
These analyses indicate that RAPID3 and RAPID3Ps show good responsiveness and 
discrimination in PsA.  In the TICOPA dataset, RAPID3 is correlated highly with the PASDAS 
score and is more discriminative than individual measures and the DAPSA score.  In the LOPAS 
dataset, RAPID3 is correlated significantly with the DAPSA and had similar responsiveness.  
We also report an estimate of the MID for improvement and smallest detectable difference 
for the RAPID3 in PsA.  
 
The RAPID3 score is a generic tool developed to assess patient status quantitatively in clinical 
practice.  It was developed in RA and has been found of value in many rheumatic conditions, 
including spondyloarthritis(4-7), osteoarthritis(8), gout(9) systemic lupus erythematosus(10) 
and other arthritides(9, 11-13).  However, in PsA, in addition to the musculoskeletal 
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manifestations, most patients also have skin psoriasis.  In these analyses, adding a skin disease 
activity VAS to create the RAPID3Ps did not show a meaningful advantage over the established 
RAPID3 score. This may be anticipated since RAPID3 measures constitute 3 of 4 in RAPID3Ps, 
skin involvement was mild in these cohorts and it may be captured at least in part in the 
patient global assessment.    
 
RAPID3 NR also performed well with the vast majority of patients who were identified as 
being in remission showing low levels of residual disease activity.  The RAPID3 measure 
includes the same 3 patient reported outcomes as the MDA criteria, and cut points for the 
patient reported items of MDA are similar to RAPID3 remission.  Since MDA requires 5 of 7 
cut points, 2 patient measures may be above the cut point, explaining why RAPID3 remission 
appears intermediate between MDA and VLDA in stringency.  Only a few cases were in RAPID3 
remission but had active disease as assessed by the physician using joint counts and skin 
scores. Nonetheless, all measures and indices are only a guide, and a clinical assessment is 
required for optimal clinical decisions.  
 
The use of the HAQ as a measure of disease activity in PsA may be questioned. The HAQ 
primarily assesses upper limb (hand) function and was developed in RA. PsA has different 
musculoskeletal manifestations (enthesitis/ dactylitis, differing joint distributions such as 
large joint monoarthritis). Furthermore it has been suggested that HAQ function scores 
become more influenced by damage than activity in established disease, potentially limiting 
responsiveness(31). However, despite these theoretical concerns we found RAPID3 to be 
sensitive to change and discriminative in early disease (TICOPA) and later disease (LOPAS), in 
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keeping with other studies showing responsiveness of HAQ even in established disease(32, 
33). 
 
Several methodological limitations are recognized in interpreting the finding of this study. The 
RAPID3 was calculated from existing outcome measures collected within the two studies.  
Therefore the HAQ-DI was used instead of the MD-HAQ and VAS scales for pain and global 
disease activity were used rather than the NRS in the RAPID3 tool.  We believe from previous 
studies that these are comparable but future research with the specific RAPID3 tool is 
required.  To maximise feasibility in clinical practice, the use of a standard tool (RAPID3) across 
all diseases appears desirable.  However, it must be noted that these patients were all 
recruited from rheumatology clinics and the average levels of skin disease were very low 
(TICOPA: median PASI 2.6, LOPAS II: median Dermatology Quality of Life Index – DLQI 2.0 and 
skin VAS 30.5/100).  The absence of a skin specific measure may limit performance in a 
population with substantial skin disease. There were also a few patients in RAPID3 remission 
who had signs of active disease on clinical assessment.  Thus, clinical assessment, in addition 
to the RAPID3 or any index, is required in all patients.  Unfortunately there was little change 
in radiographic damage over the 48 week period of the TICOPA study and radiographs were 
not routinely performed in the LOPAS study therefore the relationship between RAPID3 and 
radiographic damage has not been explored in this paper. 
 
We have not analysed possible influence of contextual factors or comorbidities on RAPID3. 
Such contextual factors as fibromyalgia are known to impact all rheumatology indices, which 
necessarily include at least one patient-reported measure independent of disease activity.  
15 
 
For example, a patient who has no swollen joints and a CRP of 10mg/L, but 14 tender joints 
and a patient global assessment of 8 would have a DAPSA of 23 even if the physician global 
assessment were “0”; the RAPID3 would be 16, assuming a pain score of 8, and both indices 
would indicate “high activity/severity.”  Similar considerations pertain to most rheumatology 
indices, as concomitant fibromyalgia was found to be associated with higher scores by 
Brikman et al in all in composite measures including the Bath Ankylosing Spondylitis Disease 
Activity Index (BASDAI), the Dermatology Life Quality Index, Leeds Enthesitis Index (LEI). 
Composite Psoriatic Disease Activity Index (CPDAI), MDA and DAPSA scores(34).  We 
emphasize again that all indices, whether RAPID3, PASDAS, DAPSA or others, must be 
informed by accompanying clinical, serological and imaging assessments in clinical practice. 
Whilst such measures should be viewed as providing valuable quantitative data which add to 
a standard medical history and physical examination toward optimal clinical decisions, an 
index should not be the only basis for a clinical decision other than in a protocol-directed 
research study.  A final limitation is that we have not assessed the stability (test re-test 
reliability) of the RAPID 3 in this study, although one would anticipate reliability similar to that 
established in other diseases (21, 35).  
We report data from two independent datasets examining the responsiveness and 
discrimination of RAPID3 in PsA. We also report data suggesting the addition of a skin 
assessment does not improve sensitivity to change in these particular cohorts. We also report 
an estimate of the MID for improvement in PsA. Taken together these data support the value 
and validity of RAPID3 as a feasible and sensitive measure of disease activity in PsA. 
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Table 1: Responsiveness of individual items and indices, ranked by t value in the TICOPA trial 
Measure Tight Control Standard Care T p 
Baseline Mean 
change 
SRM ES Baseline Mean 
change 
SRM ES 
PASDAS 5.27 -2.49 -1.45 -1.77 4.96 -1.38 -0.83 -1.09 -3.75 0.00 
RAPID3 4.18 -2.16 -1.07 -1.06 3.59 -1.01 -0.47 -0.52 -3.43 0.00 
Phys Global 44.10 -32.26 -1.57 -1.62 40.80 -19.83 -0.86 -1.27 -3.34 0.00 
Pt Global 56.15 -33.60 -1.05 -1.20 51.54 -18.64 -0.56 -0.69 -3.12 0.00 
pain VAS 53.42 -31.92 -1.05 -1.18 47.33 -17.79 -0.56 -0.68 -2.82 0.01 
DAPSA 31.24 -19.01 -1.08 -0.94 30.04 -11.45 -0.69 -0.53 -2.61 0.01 
Fatigue VAS 48.85 -21.44 -0.73 -0.78 46.39 -13.20 -0.46 -0.46 -1.84 0.07 
TJC 12.33 -6.62 -0.65 -0.56 13.22 -3.34 -0.28 -0.24 -1.57 0.12 
SJC 7.57 -6.27 -0.96 -0.97 6.82 -4.50 -0.57 -0.58 -1.22 0.22 
 
DAPSA – disease activity in psoriatic arthritis,  ES – effect size, PASDAS -  PsA disease activity score, Phys – physician, Pt – patient, RAPID3 – routine 
assessment of patient index data 3, TJC – tender joint count, SJC – swollen joint count, SRM – standardised response mean, VAS – visual analogue score
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Table 2: Discriminative capacity of disease activity state definitions in the TICOPA trial 
Measure TC % achieved StdC % achieved Chi Squared P value 
MDA 58.4 34.1 10.106 0.001 
VLDA 22.5 7.3 7.603 0.006 
RAPID3 near 
remission 
44.3 25.3 7.483 0.006 
RAPID3Ps near 
remission 
75.3 63.7 2.950 0.112 
RAPID3SJC1 42.2 22.9 7.303 0.009 
RAPID3 near 
remission or mild 
58.8 45.1 3.535 0.060 
PASDAS low 63.9 50.5 3.432 0.064 
DAPSA low (Helliwell) 76.7 65.9 2.463 0.117 
DAPSA low (JS) 70.0 58.5 2.464 0.117 
DAPSA remission (JS) 43.3 19.5 11.193 0.001 
DAPSA – disease activity in psoriatic arthritis, MDA – minimal disease activity, RAPID3 – routine 
assessment of patient index data 3, PASDAS – psoriatic arthritis disease activity score, StdC – 
standard care, TC – tight control, TICOPA – tight control of psoriatic arthritis, VLDA – very low 
disease activity 
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Table 3 - LOPAS II Sensitivity to change of the RAPID3 with other disease outcomes  
Outcome Mean change 
(sd) 
SEM SRM SDD 
RAPID3 -6.2 (9.9) 6.15 0.62 8.5 
DAPSA -18.4 (30.0) 17.6 0.61 40.8 
HAQ -0.20 (0.52) 0.29 0.38 0.4 
EQ5D VAS 9.0 (24.6) 13.8 0.37 19.2 
FACIT-Fatigue 4.4 (9.3) 5.6 0.45 7.7 
Global VAS -18.8 (31.7) 19.5 0.59 27.1 
Pain VAS -17.2 (30.1) 18.5 0.57 25.6 
Joint VAS -17.2 (31.4) 18.0 0.54 24.9 
Skin VAS -11.2 (31.1) 17.5 0.36 24.2 
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Figure 1 - Correlation between PASDAS and RAPID3 and RAPID3Ps scores at all key visits in TICOPA 
(Spearman’s rho 0.80, p<0.01 and 0.82, p<0.01) 
 
Figure 2 - Bland Altman Plot of DAPSA/ RAPID3 in LOPAS2 dataset 
 
Figure 3 - Receiver Operator Curves of DAPSA and RAPID 3 in the LOPAS dataset  
 
 
 
